Peptide users embrace self-care as healthcare trust declines

COLUMBUS, Ohio — A growing number of peptide users are adopting a more self-directed approach to managing their health as confidence in traditional healthcare institutions continues to erode, according to a new BioLongevity Supplements survey.

The survey of 586 self-identified peptide users found that 85% reported a decline in their trust in traditional healthcare over the past five years, while 76% said they now have little or no trust in the healthcare system overall.

Respondents said independent researchers are now their most trusted source of health information, followed by online communities and health influencers. Physicians ranked significantly lower, reflecting what the report describes as a shift away from institutional authority rather than a rejection of science.

The findings also suggest that peptide users are increasingly engaged in managing their own health. Nearly 80% said they primarily rely on personal research or self-experimentation when making health decisions, and 95% said using peptides changed how they think about their health and personal autonomy.

“The COVID era was a turning point for a lot of people in this community,” said Josh Felber, co-founder and CEO of BioLongevity Supplements. “Just from talking to our customers we see a large gap between what institutions are saying and what people are experiencing in their own health journeys, and that’s pushing people to take a more proactive role in their own research.”

The report argues that healthcare is evolving toward a more collaborative model in which individuals play a larger role in evaluating evidence, tracking health data and making treatment decisions alongside healthcare providers. It also suggests that supplement companies will need to prioritize transparency, third-party testing and clear scientific support to earn consumer trust.

BioLongevity said the survey was conducted online over one week in May, with respondents recruited through online communities, social media channels, and the company’s audience network. The company noted that the findings reflect the views of an engaged peptide-user population and are not representative of the broader U.S. population.